Aditxt Inc Stock Price, News & Analysis

Aditxt Therapeutics, Inc. (ADTX), a company focused on immune system health, announced a review of data from its AditxtScore™ for COVID-19 by Dr. Drew Pinsky and CEO Amro Albanna. This event is part of an ongoing clinical study measuring immunity against COVID-19. The AditxtEngage™ event is set for December 1, 2020, and will stream live from the AditxtScore™ Center. Aditxt is developing technologies aimed at immune monitoring and reprogramming, addressing issues like organ rejection and autoimmune diseases. For more details, visit Aditxt's website.

Aditx Therapeutics, Inc. (Nasdaq: ADTX) has appointed Anthony Voorhies as Head of Business Development for AditxtScore™, enhancing its immune monitoring platform. Voorhies brings extensive experience in diagnostics and medical devices, having previously worked with Calroy Health Sciences and Itamar Medical. CEO Amro Albanna anticipates Voorhies' leadership will propel AditxtScore toward proactive immune diagnosis. Aditxt focuses on technologies to improve immune health, including personalized immune profiling and immune system reprogramming.

Aditx Therapeutics (Nasdaq: ADTX) has announced that its AditxtScore™ laboratory operations for immune monitoring have received CLIA certification, enabling the launch of AditxtScore™ for COVID-19 as a Laboratory Developed Test (LDT). The operations will be co-located with Salveo Diagnostics in Richmond, VA, facilitating a targeted commercial launch in January 2021. Aditxt is also pursuing Emergency Use Authorization (EUA) from the FDA for AditxtScore™, anticipated to lead to 510(k) clearance. CEO Amro Albanna emphasized the need for ongoing immune monitoring with new vaccines coming to market.

Aditx Therapeutics (Nasdaq: ADTX) provided a business update following its Form 10-Q filing. The company successfully completed its IPO and follow-on offering, now holding $13.7 million in cash as of September 30, 2020. Key developments include the introduction of the AditxtScore™ Monitoring platform for COVID-19 antibody detection, pending FDA Emergency Use Authorization. Aditxt aims to enhance immune health through innovative technologies, focusing on personalized immune monitoring and pre-clinical immune reprogramming.

Aditxt Therapeutics, Inc. (Nasdaq: ADTX) announces the launch of AditxtEngage™, a new platform for investor engagement. The first event will take place on October 6, 2020, at 4:30 PM ET, featuring CEO Amro Albanna and moderated by Chris Lahiji of LD Micro. This initiative aims to inform stakeholders about the company’s growth and development, focusing on its biotechnologies for immune system health. Aditxt is known for its immune monitoring and reprogramming technologies, currently in the pre-clinical stage.

Aditx Therapeutics (Nasdaq: ADTX) has appointed Dr. Jeffrey Runge to its Board of Directors as an independent director, effective July 16, 2020. Dr. Runge brings over 35 years of experience in emergency medicine and public policy, notably serving as the first Chief Medical Officer at the U.S. Department of Homeland Security. His leadership experience includes overseeing significant federal health initiatives and offering guidance in medical preparedness and regulatory frameworks. Aditx focuses on developing technologies for immune system health through monitoring and reprogramming.

Aditx Therapeutics (NASDAQ: ADTX) will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 3:00 PM EDT. CEO Amro Albanna will deliver the presentation and is set for virtual one-on-one meetings with investors during the conference. Aditx focuses on advancing technologies to enhance immune system health through monitoring and reprogramming. The presentation can be accessed live via the provided webcast link.

Aditx Therapeutics announced the successful closing of a $9.6 million underwritten public offering, issuing 2,400,000 units at $4.00 each. Each unit includes one share of common stock and two types of warrants: Series A-1, exercisable at $3.19, and Series B-1, exercisable at $5.00. The warrants have a 5-year expiration. To accommodate large stakeholders, non-voting Series A Convertible Preferred Stock is also available. The offering's registration was effective as of September 1, 2020, with no intention to list the warrants or Preferred Stock. Aditx focuses on immune system health innovations.

Aditxt Therapeutics, a life sciences company focused on immunology, has appointed Dr. Drew Pinsky as Senior Advisor for their AditxtScore™ platform, effective September 1, 2020. Dr. Drew, known for his work as a physician and media personality, will assist in developing AditxtScore™, aimed at scoring immunity to COVID-19 and other diseases. His dual role includes advising on marketing strategies and introducing the platform to medical and consumer markets. Aditxt aims to enhance immune monitoring and reprogramming technologies in healthcare.